Trust signals
> Reviewed by FormBlends Medical Team · Last updated May 2026 · 14 sources cited · Author: FormBlends Editorial
Key Takeaways
- GLP-1 eligibility depends on the specific drug and its FDA-approved indications
- Diabetes-indicated GLP-1 medications require documented type 2 diabetes; obesity-indicated GLP-1 medications require BMI 30+ or 27+ with comorbidity
- Three indication expansions opened new pathways: Wegovy cardiovascular (2023), Wegovy pediatric (2023), Zepbound OSA (2024)
- Categorical exclusions apply across all GLP-1 medications: MTC history, MEN-2, pregnancy, severe hypersensitivity
- Cash-pay, manufacturer programs, and compounded paths exist for patients outside insurance coverage
Direct answer
Qualification varies by drug. Ozempic, Mounjaro, and other diabetes-indicated GLP-1 medications require an adult type 2 diabetes diagnosis. Wegovy, Zepbound, and Saxenda are obesity-indicated and require BMI 30+, BMI 27+ with weight-related comorbidity, or pediatric severe obesity (Wegovy and Saxenda for ages 12-17). Zepbound has an additional OSA-with-obesity pathway (December 2024). All GLP-1 medications exclude patients with personal or family medullary thyroid carcinoma history, MEN-2, pregnancy, or severe hypersensitivity to the drug.
Check your GLP-1 eligibility
Use our free BMI Calculator to see if you may qualify for provider-reviewed GLP-1 therapy.
Try the BMI Calculator →Table of contents
- The GLP-1 medication landscape
- Eligibility by drug
- The diabetes pathway
- The obesity pathway
- The OSA pathway (Zepbound, 2024)
- The cardiovascular pathway (Wegovy, 2023)
- Pediatric eligibility
- Categorical and relative exclusions
- Insurance and Medicare coverage
- Cash-pay and compounded paths
- Contrary view: should the gates be wider
- Decision framework by patient profile
- FAQ
- Sources
The GLP-1 medication landscape
The GLP-1 class includes multiple medications with different labeled indications, dosing schedules, and access pathways:
| Drug | Manufacturer | Indication | Dose Schedule |
|---|---|---|---|
| Ozempic (semaglutide) | Novo Nordisk | Type 2 diabetes; CV in T2D | Weekly |
| Wegovy (semaglutide) | Novo Nordisk | Obesity; CV in obesity with established CVD; pediatric obesity 12+ | Weekly |
| Rybelsus (oral semaglutide) | Novo Nordisk | Type 2 diabetes | Daily oral |
| Mounjaro (tirzepatide) | Eli Lilly | Type 2 diabetes | Weekly |
| Zepbound (tirzepatide) | Eli Lilly | Obesity; OSA with obesity | Weekly |
| Saxenda (liraglutide) | Novo Nordisk | Obesity; pediatric obesity 12+ | Daily |
| Victoza (liraglutide) | Novo Nordisk | Type 2 diabetes | Daily |
| Trulicity (dulaglutide) | Eli Lilly | Type 2 diabetes | Weekly |
| Bydureon BCise (exenatide ER) | AstraZeneca | Type 2 diabetes | Weekly |
Tirzepatide is technically a dual GIP/GLP-1 agonist rather than a pure GLP-1, but it is conventionally grouped with the class.
Eligibility by drug
Ozempic. Adults 18+ with type 2 diabetes. HbA1c 6.5%+ generally required. Insurance often adds metformin trial requirement.
Wegovy. Adults 18+ with BMI 30+ or 27+ with comorbidity. Adolescents 12-17 with BMI at or above the 95th percentile for age and sex (June 2023 pediatric expansion). Adults with established cardiovascular disease and BMI 27+ (2023 cardiovascular indication expansion based on SELECT trial).
Rybelsus. Adults 18+ with type 2 diabetes. Same indication as Ozempic in oral form.
Mounjaro. Adults 18+ with type 2 diabetes. Same requirements as Ozempic for the diabetes pathway.
Zepbound. Adults 18+ with BMI 30+ or 27+ with comorbidity. Adults 18+ with moderate-to-severe OSA and BMI 30+ (December 2024 OSA expansion).
Saxenda. Adults 18+ with BMI 30+ or 27+ with comorbidity. Adolescents 12-17 with BMI at or above the 95th percentile (December 2020 pediatric approval, body weight greater than 60 kg).
Victoza. Adults 18+ with type 2 diabetes. Also approved for adolescents 10+ with type 2 diabetes (pediatric T2D approval).
Trulicity, Bydureon. Adults 18+ with type 2 diabetes.
The diabetes pathway
Qualification for diabetes-indicated GLP-1 medications (Ozempic, Mounjaro, Trulicity, Bydureon, Victoza, Rybelsus):
- Adult age 18+ (Victoza approved down to age 10 for T2D)
- Documented type 2 diabetes by ADA criteria:
- HbA1c 6.5%+, OR
- Fasting plasma glucose 126 mg/dL+, OR
- 2-hour OGTT 200 mg/dL+, OR
- Random glucose 200 mg/dL+ with classic symptoms
- No contraindications
Insurance prior authorization typically adds:
- Recent HbA1c (within 3 months) from CLIA-certified lab
- Metformin trial documentation (typically 3+ months) or contraindication
- Sometimes: step therapy through additional medications before approving GLP-1
- Diabetes ICD-10 code (E11.x) in clinical documentation
The obesity pathway
Qualification for obesity-indicated GLP-1 medications (Wegovy, Zepbound, Saxenda):
- Adult age 18+ (Wegovy and Saxenda also approved for adolescents 12-17 with severe obesity)
- BMI 30 or higher (Class 1 obesity), OR
- BMI 27 or higher with at least one weight-related comorbidity
- Used as adjunct to reduced-calorie diet and increased physical activity
- No contraindications
Qualifying comorbidities for the 27+ BMI pathway:
- Hypertension
- Dyslipidemia
- Type 2 diabetes
- Cardiovascular disease
- Obstructive sleep apnea
Insurance prior authorization typically requires BMI documentation, comorbidity proof, lifestyle intervention records (3-6 months minimum), and sometimes a prior pharmacotherapy trial.
The OSA pathway (Zepbound, 2024)
The FDA expanded Zepbound on December 20, 2024 to include moderate-to-severe obstructive sleep apnea in adults with obesity. Criteria:
- Adult age 18+
- Moderate-to-severe OSA (AHI 15+ per hour, or AHI 5+ with daytime symptoms)
- BMI 30 or higher
- Used as adjunct to reduced-calorie diet and increased physical activity
Documentation required for the OSA pathway:
- Sleep study report (polysomnography or home sleep apnea test) within recent years
- AHI documentation meeting threshold
- BMI 30+ documentation
- Sometimes: PAP therapy trial and tolerance documentation, particularly for Medicare
The SURMOUNT-OSA trial (Malhotra et al. 2024, NEJM) supported the indication, showing AHI reductions of 25-30 events per hour with tirzepatide versus minimal change with placebo.
The cardiovascular pathway (Wegovy, 2023)
The FDA expanded Wegovy in March 2024 (following the 2023 SELECT trial publication) to include reduction of major adverse cardiovascular events (MACE) in adults with established cardiovascular disease and BMI 27+. Criteria:
- Adult age 18+
- Established cardiovascular disease (prior MI, stroke, or symptomatic peripheral artery disease)
- BMI 27 or higher
- Diabetes is not required (this is what distinguishes the indication)
The SELECT trial (Lincoff et al. 2023, NEJM) followed 17,604 patients with obesity (BMI 27+) and established cardiovascular disease without diabetes for a mean of 39.8 months. Semaglutide 2.4 mg weekly reduced MACE by 20% versus placebo. This evidence supported the cardiovascular indication and provided a Medicare coverage pathway for some patients.
Pediatric eligibility
Pediatric GLP-1 options are limited:
- Wegovy: Adolescents 12-17 with BMI at or above the 95th percentile for age and sex; body weight greater than 60 kg (June 2023 expansion based on STEP TEENS trial)
- Saxenda: Adolescents 12-17 with BMI at or above the 95th percentile (December 2020 approval)
- Victoza: Adolescents 10-17 with type 2 diabetes
Mounjaro, Zepbound, Ozempic, Trulicity, Bydureon, and Rybelsus are adult-only as of May 2026. Pediatric trials for tirzepatide (SURMOUNT-T2D, SURMOUNT-PEDS) are underway with results expected 2026-2027.
Pediatric obesity care requires specialist evaluation, family involvement, growth monitoring, and coordination with the patient's pediatrician. Adult-focused telehealth is not the appropriate care setting.
Categorical and relative exclusions
Absolute exclusions across all GLP-1 medications:
- Personal history of medullary thyroid carcinoma
- Family history of MTC in first-degree relative
- Multiple Endocrine Neoplasia syndrome type 2
- Pregnancy or planned pregnancy within 2 months (discontinue per drug-specific timeline)
- Severe hypersensitivity to the specific drug
- Active pancreatitis
Relative exclusions (case-by-case clinical judgment):
- Prior pancreatitis
- Severe gastroparesis
- Active eating disorder
- Active gallbladder disease
- Moderate to severe diabetic retinopathy without ophthalmology clearance
- Active suicidal ideation
- Severe hepatic impairment
- End-stage renal disease
- Age over 75 (no formal exclusion, but slower titration and closer monitoring)
Insurance and Medicare coverage
Commercial insurance coverage patterns:
- Diabetes-indicated GLP-1: generally covered with prior authorization for documented T2D
- Obesity-indicated GLP-1: variable; some plans cover, others exclude all weight-loss drugs categorically
- OSA-indicated Zepbound: increasingly covered following the December 2024 expansion
- Cardiovascular-indicated Wegovy: increasingly covered following the 2023 indication expansion
Medicare coverage patterns:
- Medicare Part D excludes drugs prescribed solely for weight loss (statutory exclusion)
- Diabetes-indicated GLP-1 covered for T2D
- Wegovy for cardiovascular indication: covered when established CVD documented
- Zepbound for OSA indication: covered when moderate-to-severe OSA documented
- Obesity-only indication: not covered
Medicaid coverage varies dramatically by state. Some state Medicaid programs cover obesity-indicated GLP-1 medications; others exclude all weight-loss pharmacotherapy.
Cash-pay and compounded paths
Brand cash-pay prices (May 2026):
- Ozempic: roughly $1,000-$1,200 per month
- Wegovy: roughly $1,300-$1,400 per month
- Mounjaro: roughly $1,100 per month
- Zepbound: roughly $1,060 per month at pharmacy
- Saxenda: roughly $1,300 per month
Manufacturer programs:
- LillyDirect Self Pay Journey Program (Zepbound): $349 per month for 2.5 mg single-dose vials, scaling up for higher doses
- Novo Cares (Novo Nordisk): Patient assistance program with income-based eligibility for uninsured patients
- Lilly Cares: Eli Lilly's patient assistance program with similar structure
- Manufacturer savings cards: Require commercial insurance to activate; reduce copays for covered patients
Compounded paths through 503A pharmacies:
- Compounded semaglutide: typically $200-$500 per month
- Compounded tirzepatide: typically $300-$600 per month
- Requires prescription from licensed clinician documenting medical necessity
- Not FDA-approved; not interchangeable with brand medications
Contrary view: should the gates be wider
Arguments for wider eligibility:
Metabolic risk does not align cleanly with BMI cutoffs. Patients with insulin resistance, fatty liver, dyslipidemia, and central adiposity at BMI 25-29 may benefit from GLP-1 therapy despite not meeting current thresholds.
Ethnic differences in body composition. Asian-adjusted BMI categories (obesity at 27.5+) have not been incorporated into US FDA criteria. Patients of South Asian, East Asian, and some Hispanic descent develop complications at lower BMI.
Mortality benefit may be broader than BMI gates suggest. The SELECT trial showed cardiovascular benefit in BMI 27+ patients. Whether similar benefit exists at lower BMI is unstudied.
Arguments against wider eligibility:
Side effects are real. Pancreatitis, gallbladder events, lean mass loss, and other adverse events scale with population exposure. Lower-BMI patients have less absolute benefit to offset these risks.
Cost and supply. Even with manufacturing scale-up, GLP-1 medications are expensive. Wider eligibility creates cost pressures on insurance, manufacturers, and patients with greater absolute need.
Lifestyle infrastructure. Wider drug eligibility may reduce investment in food environment, healthcare access, and behavioral support that have broader population health value.
The reasonable middle: maintain current FDA gates while supporting research into individualized risk assessment, ensure access for those meeting current criteria, and address upstream drivers of metabolic disease that pharmacotherapy cannot replace.
Decision framework by patient profile
Adult with type 2 diabetes: Diabetes-indicated GLP-1 (Ozempic, Mounjaro, Trulicity, others). Insurance coverage generally available. Discuss with primary care or endocrinology.
Adult with BMI 30+ without diabetes: Obesity-indicated GLP-1 (Wegovy, Zepbound, Saxenda). Document lifestyle attempt for prior authorization.
Adult with BMI 27-29.9 plus comorbidity: Obesity-indicated GLP-1 with comorbidity documentation. Cardiovascular Wegovy pathway if established CVD; OSA Zepbound pathway if documented sleep apnea.
Adult with established CVD and BMI 27+: Wegovy cardiovascular indication. Improved coverage including Medicare.
Adult with OSA and BMI 30+: Zepbound OSA indication. Improved coverage including Medicare.
Adolescent 12-17 with severe obesity: Wegovy or Saxenda only. Specialist or pediatric-focused care required.
Patient with boxed warning contraindication: Not eligible for any GLP-1. Discuss alternatives.
Patient with relative contraindication: Case-by-case clinician evaluation; many will decline.
FAQ
Who qualifies for GLP-1 medications? Depends on the drug and indication. Diabetes-indicated drugs require documented T2D. Obesity-indicated drugs require BMI 30+ or 27+ with comorbidity. Specific expansions exist for cardiovascular disease (Wegovy), OSA (Zepbound), and pediatric obesity (Wegovy, Saxenda).
What is the BMI requirement for GLP-1 weight loss? 30+ qualifies; 27-29.9 qualifies with comorbidity; below 27 generally does not qualify under FDA criteria.
Can teenagers qualify for GLP-1 medications? Ages 12-17 with severe obesity can qualify for Wegovy or Saxenda. Other GLP-1 medications remain adult-only.
Does Medicare cover GLP-1 medications? Covers diabetes-indicated GLP-1 for T2D. Covers Wegovy for cardiovascular indication and Zepbound for OSA indication. Excludes obesity-only weight loss coverage.
Who is excluded from GLP-1 medications? MTC history, MEN-2, pregnancy, severe hypersensitivity, active pancreatitis are categorical exclusions. Relative exclusions: prior pancreatitis, severe gastroparesis, active eating disorder.
Can I qualify without insurance? Cash-pay, manufacturer programs (LillyDirect, Novo Cares, Lilly Cares), and compounded paths exist for patients without coverage.
Can prediabetics qualify for GLP-1 medications? Not on label for diabetes-only drugs. Yes if they also meet obesity-pathway criteria. Some insurance plans accept prediabetes as a qualifying comorbidity.
What's the difference in qualification between drugs? Diabetes-only labels require T2D. Obesity labels require BMI 30+ or 27+ with comorbidity. Specific drugs have additional indication-specific pathways.
Sources
- FDA. Ozempic Prescribing Information. Current revision 2025.
- FDA. Wegovy Prescribing Information, including pediatric and cardiovascular indications. Current revision 2025.
- FDA. Mounjaro Prescribing Information. Current revision 2025.
- FDA. Zepbound Prescribing Information, including OSA indication. Current revision 2025.
- FDA. Saxenda Prescribing Information. Current revision 2024.
- Wilding JPH et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity (STEP 1). NEJM. 2021.
- Jastreboff AM et al. Tirzepatide Once Weekly for the Treatment of Obesity (SURMOUNT-1). NEJM. 2022.
- Lincoff AM et al. Semaglutide and Cardiovascular Outcomes in Obesity Without Diabetes (SELECT). NEJM. 2023.
- Malhotra A et al. Tirzepatide for the Treatment of Obstructive Sleep Apnea and Obesity (SURMOUNT-OSA). NEJM. 2024.
- Weghuber D et al. Once-Weekly Semaglutide in Adolescents with Obesity (STEP TEENS). NEJM. 2022.
- American Diabetes Association. Standards of Medical Care in Diabetes, 2025.
- Centers for Medicare and Medicaid Services. Part D Coverage of GLP-1 Agonists Update. 2025.
- Endocrine Society. Pharmacological Management of Obesity Clinical Practice Guideline. 2023 update.
- American Academy of Pediatrics. Clinical Practice Guideline for the Evaluation and Treatment of Children and Adolescents with Obesity. Pediatrics. 2023.
Footer disclaimers
Platform Disclaimer. FormBlends connects adult patients with independent licensed clinicians and U.S.-based pharmacies. Eligibility for any GLP-1 medication is determined by a clinician based on clinical evaluation. We do not serve pediatric patients.
Compounded Medication Notice. Compounded semaglutide and tirzepatide are prepared by state-licensed 503A pharmacies in response to individual prescriptions. They are not FDA-approved and are not interchangeable with brand Ozempic, Wegovy, Mounjaro, or Zepbound.
Results Disclaimer. Trial outcomes (STEP 1, SURMOUNT-1, SELECT, SURMOUNT-OSA, STEP TEENS) reflect average results in study populations. Individual outcomes vary based on adherence, baseline health, comorbidity profile, and concurrent therapy.
Trademark Notice. Ozempic, Wegovy, Rybelsus, Saxenda, and Victoza are trademarks of Novo Nordisk A/S. Mounjaro and Zepbound are trademarks of Eli Lilly and Company. Trulicity is a trademark of Eli Lilly. Bydureon is a trademark of AstraZeneca. FormBlends is not affiliated with these manufacturers.